|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Alberta Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing AlbertaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Parvus Therapeutics
| | | Phone: | (403) 708-3401 | Year Established: | 2009 | Employees: | 5 | Main Contact: | Janice M. LeCocq, Ph.D., Chairman & CEO | | Company Description | Parvus is pioneering a breakthrough class of disease-specific biological therapeutics called NavacimsTM that are designed to halt and potentially cure autoimmune disease by restoring immune tolerance. The Company’s robust therapeutic platform is capable of generating a rich pipeline of therapeutic candidates for a wide range of autoimmune diseases. Parvus has validated two lead drug candidates to take into clinical development for Type 1 diabetes (T1D) and Multiple Sclerosis (MS), and is scaling up drug product manufacture for GLP toxicology studies.
Parvus operates as a virtual company, maintaining limited office space at the Alastair Ross Technology Center. Their scientific operations are located at the Health Research Innovation Centre, part of the Faculty of Medicine at the University of Calgary. | |
|
|
|
|
|